Piper Sandler Raises Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $140.00
Ultragenyx Pharmaceutical (NASDAQ:RARE – Free Report) had its target price upped by Piper Sandler from $135.00 to $140.00 in a research note released on Monday morning,Benzinga reports. Piper Sandler currently has an overweight rating on the biopharmaceutical company’s stock. Several other research firms also recently weighed in on RARE. JPMorgan Chase & Co. decreased their […]
More Stories
SPDR Portfolio Emerging Markets ETF (NYSEARCA:SPEM) Shares Sold by Financial Enhancement Group LLC
Financial Enhancement Group LLC trimmed its stake in shares of SPDR Portfolio Emerging Markets ETF (NYSEARCA:SPEM – Free Report) by...
Insteel Industries (NASDAQ:IIIN) Posts Quarterly Earnings Results, Misses Estimates By $0.03 EPS
Insteel Industries (NASDAQ:IIIN – Get Free Report) released its quarterly earnings data on Thursday. The industrial products company reported $0.06...
LuxUrban Hotels (NASDAQ:LUXH) Faces Delisting from Nasdaq
LuxUrban Hotels Inc., a Delaware-based hotel company, recently received notice from The Nasdaq Stock Market LLC (Nasdaq) indicating that the...
BigBear.ai Holdings, Inc. Updates Pro Forma Financial InformationBigBear.ai Holdings, Inc. (Exact name of registrant as specified in its charter) made a recent filing with the United States Securities and Exchange Commission to provide an update on c
This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For...
Beech Hill Advisors Inc. Cuts Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)
Beech Hill Advisors Inc. reduced its position in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 2.4% during the fourth...
Uranium Royalty Corp. (NASDAQ:UROY) Short Interest Up 34.9% in December
Uranium Royalty Corp. (NASDAQ:UROY – Get Free Report) was the target of a large increase in short interest in December....